Citigroup’s Intersect ENT, Inc XENT Stock Holding History

Citigroup’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-800	Closed	-$18K	–	7757
2020 Q4	$18K	Sell	800 -6,500	-89%	-$124K	﹤0.01%	6730
2020 Q3	$119K	Sell	7,300 -700	-9%	-$12.7K	﹤0.01%	4982
2020 Q2	$108K	Sell	8,000 -9,300	-54%	-$108K	﹤0.01%	5516
2020 Q1	$205K	Buy	17,300 +17,100	+8,550%	+$379K	﹤0.01%	4714
2019 Q4	$5K	Buy	+200	New	+$4.05K	﹤0.01%	7418
2019 Q3	–	Sell	-2,100	Closed	-$48K	–	7879
2019 Q2	$48K	Buy	+2,100	New	+$56.6K	﹤0.01%	6527
2018 Q4	–	Sell	-94,200	Closed	-$2.71M	–	7890
2018 Q3	$2.71M	Buy	+94,200	New	+$2.83M	﹤0.01%	2451

Citigroup's XENT Position: Q2 2022 in Review

Citigroup sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 2,231 shares — an estimated $63K sold.

Citigroup first reported a position in XENT in Q3 2014 and held it in 31 quarters. The position peaked at $9.47M in Q3 2021. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

Citigroup reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
Citigroup sold 2,231 Intersect ENT, Inc shares in Q2 2022, an estimated $63K.
Citigroup first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 31 quarters.
Citigroup's Intersect ENT, Inc position peaked at $9.47M in Q3 2021.
0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Citigroup's 13F filing for Q2 2022, filed 10 Aug 2022.